A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.

Inclusion Criteria: * patients according to diagnostic standards on western medical ischemic stroke; * patients according to diagnostic standards on Chinese medical attack to meridians; * patients according to differentiation standards on syndrome of intermingled phlegm and blood stasis; * 2 weeks to 6 months after attack; * Age between 18-80 years; * patients must volunteer to participate in this study and sign the informed consent form. Exclusion Criteria: * patients accompanying unconsciousness or severe dementia; * ALT, AST≥2 times of upper limit of normal; * patients with other severe diseases such as disease in circulatory system, hematopoietic system, digestive system, endocrine system etc; * patients allergic to Ginkgo biloba drugs，Meglumine and meglumine agents; * patients who are pregnant, lactating or planning for pregnancy; * patients with insanity; * patients who are not suitable for clinical trial under doctors' consideration; * patients with Merge bleeding after infarction or patients with hemorrhagic tendency; * patients with lower extremity venous thrombosis; * patients who have participated in other clinical trial within 1 month.